UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 82 filers reported holding UROGEN PHARMA LTD in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $809,862 | +70.4% | 57,806 | +25.9% | 0.00% | – |
| Q2 2023 | $475,272 | -19.2% | 45,920 | -32.0% | 0.00% | – |
| Q1 2022 | $588,000 | +2.6% | 67,486 | +11.9% | 0.00% | – |
| Q4 2021 | $573,000 | -44.5% | 60,289 | -1.7% | 0.00% | – |
| Q3 2021 | $1,032,000 | +20.6% | 61,334 | +9.4% | 0.00% | – |
| Q2 2021 | $856,000 | -17.1% | 56,057 | +5.7% | 0.00% | – |
| Q1 2021 | $1,033,000 | +10.5% | 53,031 | +2.2% | 0.00% | – |
| Q4 2020 | $935,000 | -9.8% | 51,886 | -3.5% | 0.00% | – |
| Q3 2020 | $1,037,000 | -28.2% | 53,753 | -2.8% | 0.00% | – |
| Q2 2020 | $1,444,000 | +67.9% | 55,313 | +14.8% | 0.00% | – |
| Q1 2020 | $860,000 | -46.6% | 48,196 | -0.1% | 0.00% | – |
| Q4 2019 | $1,610,000 | +46.1% | 48,235 | +4.3% | 0.00% | – |
| Q3 2019 | $1,102,000 | -31.0% | 46,243 | +4.0% | 0.00% | – |
| Q2 2019 | $1,598,000 | +279.6% | 44,448 | +398.1% | 0.00% | – |
| Q3 2018 | $421,000 | – | 8,923 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
| Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
| Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
| MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
| DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
| SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
| BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
| Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |